NCT05467514View on ClinicalTrials.gov

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Liraglutide

Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus

Trial Locations (1)

Unknown

Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25, Monterrey

All Listed Sponsors
collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

lead

David Sanchez Garcia

OTHER_GOV